Table VI.

Risk Difference Analysis of BMI or WHR and high-grade PC

Body Size Measure	Model Covariate		OR(body size)	95% CI(body size)	P(body size)	P(biomarker)
BMI (>30 kg/m vs. ≤30 kg/m)	base model*		4.88	1.79, 13.3	0.002	----
	+ leptin		4.13	1.23, 13.8	0.022	0.633
	+ c-peptide		4.23	1.52, 11.8	0.006	0.234
	+ adiponectin		5.20	1.86, 14.6	0.002	0.214
	+ estradiol		4.58	1.66, 12.6	0.003	0.731
	+ all**		4.07	1.14, 14.5	0.030	---
WHR (>1.01 vs. ≤1.01)	base model		2.52	1.02, 6.23	0.046	-----
	+ leptin		2.45	0.96, 6.29	0.062	0.022
	+ c-peptide		2.23	0.88, 5.68	0.090	0.079
	+ adiponectin		2.81	1.11, 7.12	0.030	0.228
	+ estradiol		2.39	0.96, 5.96	0.061	0.702
	+ all		2.41	0.91, 6.41	0.078	----

Analysis of obesity and high-grade PC restricted to men without prostate enlargement (prostate volume < 40 ml).

^*base model investigating the association between BMI/WHR with high-grade PC included age, alpha blocker use, treatment for diabetes, and number of cores at biopsy. Leptin or other listed biomarkers were then added individually to the base model, and the adjusted OR, 95% CI, and p-value for each body size measure (BMI/WHR) is reported. The p-value for the biomarker within the model is also listed. A change in the OR from the base model would suggest that biomarker is a mediator.

^**model includes all biomarkers together with the base model.